omeprazole and s 1743

omeprazole has been researched along with s 1743 in 222 studies

Research

Studies (222)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's129 (58.11)29.6817
2010's73 (32.88)24.3611
2020's20 (9.01)2.80

Authors

AuthorsStudies
Andersson, T; Hasselgren, G; Holmberg, J; Jonsson, A; Kylebäck, A; Lind, T; Röhss, K; Rydberg, L1
Faulds, D; Spencer, CM1
Collins, DW; D'Amico, D; Falk, GW; Hamelin, B; Joelsson, B; Johnson, DA; Kahrilas, PJ; Schmitt, C; Whipple, J1
Cockeram, A; De Argila, CM; Delchier, JC; Göthe, L; Hasselgren, G; Labenz, J; Lauritsen, K; Lind, T; Sinclair, P; Stubberöd, A; Treichel, HC; Veldhuyzen Van Zanten, S; Wrangstadh, M1
Benjamin, SB; Damico, D; Goldstein, JL; Hamelin, B; Johnson, DA; Lamet, M; Vakil, NB; Whipple, J1
Talley, NJ; Thitiphuree, S1
Bang, C; Delle, M; Junghard, O; Lauritsen, K; Lind, T; Moum, B; Omland, TM; Schulz, T; Talley, NJ; Tunturi-Hihnala, H1
Breiter, JR; Hamelin, B; Hwang, C; Johanson, J; Kahrilas, PJ; Levine, JG; Marino, V; Maton, P; Richter, JE1
Robinson, M2
Andersson, T; Hassan-Alin, M; Hasselgren, G; Röhss, K; Weidolf, L1
Andersson, T; Hassan-Alin, M; Hasselgren, G; Röhss, K1
Andersson, T; Bredberg, E; Hassan-Alin, M; Röhss, K1
Edwards, SJ; Lind, T; Lundell, L2
Bartuzi, Z; Dite, P; Hasselgren, G; Kleczkowski, D; Kryszewski, A; Larkö, A; Rudzinski, J; Tulassay, Z; Wrangstadh, M1
Kromer, W1
Savarino, V; Scarpignato, C; Tonini, M; Vigneri, S2
Kale-Pradhan, PB; Landry, HK; Sypula, WT1
Green, J; Higgins, A; Junghard, O; Wahlqvist, P2
Dunn, CJ; Mallarkey, G; Scott, LJ; Sharpe, M2
Katz, PO; Ramakrishnan, A1
Hasselgren, G; Hedenström, H; Röhss, K1
Laine, L1
Baker, DE2
Hedge, DD; Johnson, TJ1
Tahboub, RM; Vanderhoff, BT1
Armstrong, D; Bardhan, KD; Carlsson, RG; Chen, S; Giaffer, M; Green, JR; Hasselgren, GS; O'Kane, KP; Talley, NJ; Venables, TL1
Louis, E1
Cheer, SM; Faulds, D; Lamb, HM; Prakash, A1
Johnson, DA1
D'Anna, L; Figura, N; Gatta, L; Holton, J; Miglioli, M; Perna, F; Ricci, C; Vaira, D1
Carlsson, E; Lindberg, P; Olbe, L1
Kendall, MJ1
Dent, J2
Andersson, T; Carlsson, E; Fryklund, J; Keeling, D; Lindberg, P; Lundborg, P1
Bianchi Porro, G; Pace, F; Pallotta, S1
Kurilo, AE; Maev, IV; Shchekina, MI; V'iuchnova, ES1
Hogan, D; Pratha, V; Sachs, G; Shin, JM1
Edin, R; Falk, A; Hatlebakk, JG; Johnsson, F; Klintenberg, AC; Román, J; Stubberöd, A; Toth, E1
Lee, J; Machado, S; Veldhuyzen Van Zanten, S1
Hellström, PM; Vitols, S1
Calvet, X; Gisbert, JP; Vallve, M; Vergara, M1
Bästlein, E; Bayerdörffer, E; Buchner, M; Ebert, S; Haferland, C; Kirsch, C; Lehn, N; Miehlke, S; Neumeyer, M; Schneider-Brachert, W; Stolte, M; Vieth, M1
Balashova, NN; Maev, IV; Shchekina, MI; Viuchnova, ES1
Chang, YM; Chuang, CH; Huang, SF; Kao, AW; Kao, YH; Lai, YL; Sheu, BS; Sheu, MJ1
Chen, Y; Katz, PO; Miner, P; Sostek, M1
Kivioja, A; Linnosmaa, I; Vehviläinen, A; Vohlonen, I1
Andersson, T1
Gisbert, JP; Pajares, JM1
Gatta, L; Miglioli, M; Osborn, JF; Perna, F; Ricci, C; Tampieri, A; Vaira, D; Vakil, N1
Anagnostopoulos, GK; Arvanitidis, D; Kostopoulos, P; Margantinis, G; Tsiakos, S1
Aeed, H; Avni, Y; Boaz, M; Levine, A; Moss, SF; Niv, Y; Shabat-Sehayek, V; Shevah, O; Shirin, H1
de Korwin, JD; Ducrotté, P; Vallot, T1
Ahlström, M; Andersson, TB; Li, XQ; Weidolf, L1
Armstrong, D; Bigard, MA; Green, J; Junghard, O; Lauritsen, K; Lind, T; Mössner, J; Moum, B; Talley, NJ; Tunturi-Hihnala, H; Venables, T1
Lind, T; Röhss, K; Wilder-Smith, C1
Freston, JW1
Arancia, G; Belardelli, F; De Milito, A; Fais, S; Federici, C; Iessi, E; Logozzi, M; Lozupone, F; Luciani, F; Lugini, L; Marra, M; Molinari, A; Montinaro, A; Parmiani, G; Rivoltini, L; Spada, M1
Andersson, T; Hassan-Alin, M; Niazi, M; Röhss, K1
Orr, WC1
Chen, TW; Cheng, HC; Hunag, SF; Kao, AW; Lu, CC; Sheu, BS; Wu, JJ1
Ortiz, V; Ponce, J; Velasco, MJ1
Chang, FY; Chen, CY; Lai, YL; Lee, SD; Lu, CL; Luo, JC1
Furuta, T; Hishida, A; Ishizaki, T; Nakamura, A; Shirai, N; Sugimoto, M1
Bagel-Boithias, S; Chopineau, J; Messaouik, D; Sautou-Miranda, V1
Abelson, TI; Hicks, DM; Khandwala, F; Milstein, C; Park, W; Richter, JE; Vaezi, MF1
Herszenyi, L; Hritz, I; Molnar, B; Pronai, L; Tulassay, Z1
Chen, YH; Li, HY; Wang, H; Wang, WM1
Domínguez-Martín, A; Domínguez-Muñoz, A; Gisbert, JL; Gisbert, JP; Marcos, S1
Brown, RE; Remák, E; Robinson, A; Yuen, C1
Calvet, X; Gomollón, F1
Hofmann, U; Klotz, U; Schwab, M; Treiber, G1
Hofmann, U; Klotz, U; Leodolter, A; Malfertheiner, P; Schaeffeler, E; Schwab, M; Treiber, G1
Hamelin, B; Hwang, C; Lightdale, CJ; Schmitt, C2
Dohmen, W; Fuchs, W1
Clark, DW; Strandell, J1
Fang, JY; Lu, R; Sun, DF; Wang, X1
Bästlein, E; Bayerdörffer, E; Hansky, K; Jacobs, E; Kirsch, C; Kuhlisch, E; Lehn, N; Madisch, A; Miehlke, S; Morgner, A; Schneider-Brachert, W; Stolte, M1
Blume, H; Donath, F; Schug, BS; Warnke, A1
Klotz, U1
Hultman, Ia; Liljeblad, M; Stenhoff, H1
Bakshi, A; Bungay, K; Devlin, JW; Olsen, KM1
Bagin, RG; Ballard, ED; Checani, GC; Gautille, TC; Hogan, DL; Katz, PO; Koch, FK; Pratha, VS1
Molnar, B; Mullner, K; Tulassay, Z1
Arigbabu, A; Bachelet, E; Cardona, HJ; Hammour, AA; Miller, T; Subei, IM; Useche, E1
Baldassarre, E; Bianchetti, MG; Ferrarini, A; Sagaon, MM1
Junghard, O; Wiklund, IK1
Cianciolo, G; Comai, G; Feliciangeli, G; Stefoni, S1
Fjellman, M; Kilhamn, J; Lind, T; Röhss, K; Wilder-Smith, C1
Brazowski, J; Czerwionka-Szaflarska, M1
Cho, YK; Choi, HS; Hwang, SJ; Jeon, WK; Kim, BI; Kim, HJ; Park, DI; Park, JS; Sohn, CI1
Bastaki, SM; Chandranath, IS; Singh, J1
Pai, N; Pai, V1
Davies, M; Shakir, SA; Wilton, LV1
Andersson, T; Weidolf, L1
Armstrong, D; Chen, Y; Hunt, RH; James, C; Lee, E; Leonard, J; Sachs, G; Shin, JM; Tang-Liu, D; Yaghoobi, M1
Giannoulis, E; Karamanolis, G; Ladas, SD; Theofanidou, I; Triantafyllou, K; Yiasemidou, M1
Charlemagne, A; Fagnani, F; Le Jeunne, P; Mouly, S1
Estborn, L; Joelson, S1
Caron, J; Durlach, V; François, M; Lévy-Bohbot, N1
Aloumanis, V; Ben, M; Chan, P; Kupiec, TC; Patterson, J; Trissel, LA1
Blick, SK; Croxtall, JD; Keating, GM; Lyseng-Williamson, KA; McKeage, K1
Calvet, X; Garcia, P; Gisbert, JP; Vergara, M; Villoria, A1
Dragomir, D; Hurduc, V; Plesca, D; Sajin, M; Vandenplas, Y1
Leufkens, HG; Martini, N; Sagliocca, L; Tafuri, G; Traversa, G; Trotta, F1
Gursoy, O; Memiş, D; Sut, N1
Farrell, CP; Gabello, M; Martin, AP; Morgan, M; Mullin, JM; Murray, LJ; Rudolph, DS; Underwood, JC; Valenzano, MC1
Cho, YK; Choi, WH; Hong, CH; Hong, EJ; Jeon, WK; Kim, BI; Kim, HJ; Oh, SJ; Park, DI; Park, JH; Shon, CI; Song, MJ1
Christ, G; Jilma, B; Kreiner, G; Lang, IM; Siller-Matula, JM; Spiel, AO1
Brunet, C; Dine, T; Dupin-Spriet, T; Gressier, B; Kambia, NK; Luyckx, M1
Mattia, AR; Wilcox, GM1
Huang, Z; Shi, R; Wang, J; Wang, X; Xu, Z; Yang, Y; Zhang, G; Zhao, F1
Zheng, RN1
Braun, S; Hadamitzky, M; Kastrati, A; Morath, T; Schömig, A; Sibbing, D; Stegherr, J; Vogt, W; von Beckerath, N1
Chang, WL; Chen, WY; Cheng, HC; Sheu, BS; Tsai, YC; Yeh, YC1
Hsu, YC; Lin, HJ; Perng, CL; Tsai, JJ1
DAS, R; Edwards, SJ; Lind, T; Lundell, L1
Saccar, CL1
Groeneveld, L; Hoogendoorn, RJ; Kwee, JA1
Dobrovol'skiĭ, OV; Kondratenko, SN; Pisarev, VV; Serebrova, SIu; Starodubtsev, AK; Vasilenko, GF1
Hunt, RH; Padol, S; Yaghoobi, M; Yuan, Y1
Cirilli, R; Ferretti, R; Gallinella, B; La Torre, F; Mosca, A; Sanna, ML; Zanitti, L1
Börgel, J; Endres, HG; Engelhardt, A; Krüger, JC; Lask, S; Mügge, A; Neubauer, H1
Brikova, SI; Bushkova, EV; Kazakova, RV; Onuchina, EV; Peshkov, DV; Poshkaĭte, IA; Rozhanskiĭ, AA; Tsukanov, VV1
Azevedo, F; Barros, AM; Baudrier, T; Cadinha, S; Cunha, AP; Morais, P; Mota, A1
Cristofari, F; De Francesco, V; Hassan, C; Manes, G; Scaccianoce, G; Zullo, A1
Agranat, I; Marom, H1
den Hoed, CM; Kuipers, EJ1
Grossmann, D; Knoth, H; Kuhlisch, E; Laass, M; Labenz, J; Löbe, S; Madisch, A; Miehlke, S; Morgner, A1
Davis, DA; Johnson, JT; Neill, KK1
Chandrashekhar, VM; Phadatare, PD1
Keating, GM1
Hasenfuss, G; Maier, L; Schillinger, W; Schmitto, J; Schotola, H; Schwörer, H; Sohns, C; Sossalla, S; Toischer, K1
Illueca, M; Johnson, DA; Monyak, JT; Sharma, P1
Babiak, P; Hájíček, J; Kyslík, P; Kyslíková, E; Marešová, H; Palyzová, A; Stěpánek, V; Valešová, R1
Boot, H; de Boer, A; Deneer, VH; Harmsze, AM; Heringa, M; le Comte, M; Mol, PG; Schalekamp, T; Verduijn, MM; Verheugt, FW1
Yeomans, ND1
Buckley, DB; Kazmi, F; Ogilvie, BW; Paris, BL; Parkinson, A; Rostami-Hodjegan, A; Toren, P; Yerino, P1
Htun, WW; Huang, Y; Ko, W; Kwan, J; Kwan, TW1
Chen, PF; Hsiao, FY; Huang, WF; Mullins, CD; Tsai, YW; Wen, YW1
Kwok, CS; Loke, YK1
Bhatt, DL; Brooks, JK; Frelinger, AL; Lee, RD; Michelson, AD; Mulford, DJ; Nigam, A; Nudurupati, S; Wu, J1
de Boer, A; le Cessie, S; Maitland-van der Zee, AH; Redekop, WK; Schalekamp, T; van der Meer, FJ; van Schie, RM; Verhoef, TI; Zuurhout, MJ1
Ding, J; Fan, D; Gyawali, PC; Liu, L; Liu, N; Wu, K; Yang, Y; Yao, L; Zhang, D; Zhang, H1
Chang, SY; Chen, C; Chimalakonda, A; Hurley, J; Rodrigues, AD; Thorndike, D; Vuppugalla, R; Wagner, A; Yang, Z; Zvyaga, T1
Kadoyama, K; Okuno, Y; Sakaeda, T; Tamura, T1
Bytzer, P; Mattsson, H; van Zanten, SV; Wernersson, B1
Simpson, SE1
Chularojanamontri, L; Dhana, N; Jiamton, S; Jongjarearnprasert, K; Kulthanan, K; Manapajon, A; Suvanasuthi, S1
Banahan, BF; Bentley, JP; Datar, MV; Mahabaleshwarkar, RK; Null, KD; Strum, MW; Yang, Y1
Kasugai, K; Kinoshita, Y; Miwa, H2
Almebayadh, M; Avril, MF; Carlotti, A; Dupin, N; Goulvestre, C; Le Guern, V; Mouthon, L; Regnier-Rosencher, E1
Metz, DC; Shah, P; Singh, MH; Yang, YX1
Hatlebakk, JG; Jonasson, C; Tvete, IF1
Furuta, T; Ichikawa, H; Iwaizumi, M; Miyajima, H; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Yamada, T; Yamade, M1
Angioli, R; Damiani, P; Improta, G; Petrella, C; Plotti, F; Scarpignato, C; Severini, C; Signore, F; Terranova, C1
Cho, KB; Jang, BI; Jeon, SW; Jung, JT; Jung, MK; Jung, YS; Kim, ES; Kim, EY; Kim, KO; Kim, WJ; Kwon, JG; Lee, SH; Oh, MJ; Park, CS; Park, KS; Yang, CH1
Baynham, MT; Blankley, RT; Butler, CF; Fisher, K; Leys, D; McLean, KJ; Munro, AW; Peet, C; Rigby, SE; Voice, MW1
Agranat, I; Marom, H; Pogodin, S1
Andersson, T; Galbraith, H; Nagy, P; Niazi, M; Nylander, S; Ranjan, S; Wallentin, L1
Bertino, JS1
Kim, EH; Kim, HY; Lee, SK; Park, CH; Roh, YH1
Bilker, WB; Brensinger, CM; Flockhart, DA; Freeman, CP; Hennessy, S; Kasner, SE; Kimmel, SE; Leonard, CE1
Liu, F; Shokrollahi, H1
Attwood, SE; Eklund, S; Ell, C; Fiocca, R; Galmiche, JP; Hasselgren, B; Hatlebakk, JG; Jahreskog, M; Långström, G; Lind, T; Lundell, L1
Dan, YY; Khoo, AL; Lim, BP; Lin, L; Teng, M; Wu, TS; Zhao, YJ1
Barocelli, E; Bettini, R; Castrati, L; Colombo, P; Elviri, L; Flammini, L; Rossi, A1
Akers, KS; Boyd, NK; Niece, KL1
Fossmark, R; Hauso, Ø; Waldum, HL1
Alber, H; Amann, A; Beer, B; Hofstaetter, S; Klieber, M; Modak, A; Neururer, M; Oberacher, H1
Liu, L; Qi, Q; Wang, R; Wang, S; Zhao, F1
Becker, ML; Franken, WP; Karapinar, F; Schalekamp, T; van der Hoeven, RT; Verzijl-Zeegers, R1
Asghar, W; Jamali, F; Pittman, E1
Abbas, MG; Akter, N; Akter, S; Bhuiyan, MA; Hassan, MR; Shahriar, M1
Barbeau, G; Bertrand, OF; De Larochellière, R; Déry, JP; Déry, U; Gleeton, O; Harvey, A; Larose, É; Modak, A; Nguyen, CM; Noël, B; Paradis, JM; Proulx, G; Rinfret, S; Rodés-Cabau, J; Roy, L; Roy, M1
Christensen, RD; Haastrup, PF; Hansen, JM; Jarbøl, DE; Paulsen, MS; Søndergaard, J1
Balza, E; Carta, S; Castellani, P; Gattorno, M; Lavieri, R; Piccioli, P; Rubartelli, A; Semino, C1
Chen, MH; Chu, CJ; Hou, MC; Huang, YH; Lee, FY; Lin, HC; Lu, CL; Su, TP; Tsai, CF; Wang, YP1
Badowski, M; Hung, YT; Law, EH; Lee, TA; Sanchez, A; Weems, K1
Chang, YC; Hsiao, CJ; Hsiao, PJ; Wu, KL1
Klyarytska, I; Kriviy, V; Modak, AS; Rabotyagova, Y; Tsapyak, T1
Damanhuri, NS; Kumolosasi, E; Omar, MS1
Eklund, S; Lau, J; Lind, T; Persson, T1
El-Kimary, EI; Ragab, MAA2
Sebastián Domingo, JJ1
Bell, R; Dart, AJ; Huxford, KE; Jeffcott, LB; Perkins, NR1
Li, MJ; Li, Q; Liu, LQ; Sun, M1
Chen, D; Fei, G; Lu, B; Wang, B; Wang, J; Wang, X; Wu, B; Zhang, L; Zou, D; Zou, X1
Hatakeyama, S; Hosogoe, S; Imanishi, K; Ohyama, C; Okamoto, T; Saitoh, F; Suzuki, T; Takashima, T; Tanaka, Y1
Calissendorff, J; Falhammar, H; Lindh, JD; Mannheimer, B; Nathanson, D; Skov, J1
Türkeş, C1
Karimova, MM; Makarenko, OV; Masheiko, AM; Onul, NM1
Johansson, E; Karlsson, A; Ludvigsson, JW1
Barbeito Castiñeiras, G; Bardán García, B; Belles Medall, D; Blanco Dorado, S; Blanco Hortas, A; Campos-Toimil, M; Carracedo, Á; Fernández-Ferreiro, A; Gómez Márquez, A; Lamas, MJ; Latorre-Pellicer, A; López-Vizcaíno, A; Maroñas Amigo, O; Otero Espinar, F; Pérez Del Molino Bernal, ML; Rodríguez Jato, MT; Zarra Ferro, I1
Abed, MN; Alassaf, FA; Alfahad, M; Jasim, MHM; Qazzaz, ME1
Hongo, M; Hunt, RH; Lazarescu, A; Lottrup, C; Scarpignato, C; Stein, E; Wu, JCY1
Diao, A; Hao, Y; Li, Y; Liu, Y; Liu, Z; McKenzie, EA; Tao, L; Wang, D; Zhang, W; Zhao, Q; Zhao, T1
Chen, F; Fang, B; He, X; Wang, S1
Hancu, G; Kelemen, H; Papp, LA; Tóth, G1
Daali, Y; Desmeules, JA; Lenoir, C; Niederer, A; Rollason, V; Samer, CF1
Chan, AT; Choi, HK; Lei, G; Lu, N; Misra, D; Neogi, T; Wei, J; Zeng, C; Zhang, Y1
Baars, MD; Broekhuizen, M; Cornette, J; Danser, AHJ; Koch, BCP; Neuman, RI; Nieboer, D; Russcher, H; Saleh, L; Schoenmakers, S; van den Berg, SAA; van den Meiracker, AH; Verhoeven, M; Visser, W1
Barbé, F; Buti, M; de Batlle, J; Galván, L; Piñol-Ripoll, G; Torres-Bondia, F1
Bardou, M; Ben Ghezala, I; Luu, M1
Chen, P; Fan, K; Luo, P; Peng, J; Wang, X; Zhang, Z; Zhu, X1
Lespessailles, E; Toumi, H1
Calissendorff, J; Falhammar, H; Issa, I; Lindh, JD; Mannheimer, B; Skov, J1
da Mota, AD; da Rosa, TF; de Paula, BR; Foletto, VS; Franco, LN; Hörner, R; Marion, SL; Serafin, MB1
Denda, M; Goda, M; Hamano, H; Higashionna, T; Ishizawa, K; Lin, TJ; Miyata, K; Nawa, H; Neishi, M; Niimura, T; Yagi, K; Zamami, Y1
Häyrynen, S; Kiiski, JI; Niemi, M; Ramste, M; Ritvos, M; Sinisalo, J1
Afzal, NA; Andrews, E; Beattie, RM; Hayen, A; Liddicoat, I; Tighe, MP1

Reviews

65 review(s) available for omeprazole and s 1743

ArticleYear
Esomeprazole.
    Drugs, 2000, Volume: 60, Issue:2

    Topics: Animals; Anti-Ulcer Agents; Clinical Trials as Topic; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Helicobacter pylori; Humans; Omeprazole; Stereoisomerism

2000
Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy.
    International journal of clinical practice, 2000, Volume: 54, Issue:8

    Topics: Adult; Aged; Anti-Ulcer Agents; Area Under Curve; Biological Availability; Esomeprazole; Esophagitis, Peptic; Female; Half-Life; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Treatment Outcome

2000
New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
    European journal of gastroenterology & hepatology, 2001, Volume: 13 Suppl 1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Gastroesophageal Reflux; Genotype; Humans; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole

2001
Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.
    Clinical pharmacokinetics, 2001, Volume: 40, Issue:6

    Topics: Animals; Enzyme Inhibitors; Esomeprazole; Humans; Isomerism; Microsomes, Liver; Omeprazole

2001
Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole.
    Clinical pharmacokinetics, 2001, Volume: 40, Issue:7

    Topics: Anti-Ulcer Agents; Area Under Curve; Drug Interactions; Esomeprazole; Half-Life; Humans; Intestinal Absorption; Omeprazole; Stereoisomerism

2001
Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis.
    Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:11

    Topics: Administration, Oral; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esomeprazole; Esophagitis, Peptic; Humans; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome

2001
Improving opportunities for effective management of gastro-oesophageal reflux disease.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2001, Volume: 33, Issue:8

    Topics: Anti-Ulcer Agents; Biological Availability; Esomeprazole; Esophagitis; Gastric Mucosa; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Isomerism; Omeprazole; Proton Pump Inhibitors; Treatment Outcome

2001
Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2001, Volume: 33, Issue:7

    Topics: Anti-Ulcer Agents; Drug Interactions; Esomeprazole; Humans; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Zollinger-Ellison Syndrome

2001
Esomeprazole for acid peptic disorders.
    The Annals of pharmacotherapy, 2002, Volume: 36, Issue:4

    Topics: Absorption; Anti-Ulcer Agents; Clinical Trials as Topic; Esomeprazole; Esophagitis, Peptic; Humans; MEDLINE; Omeprazole; Treatment Outcome

2002
Pharmacologic management of gastroesophageal reflux disease.
    Current gastroenterology reports, 2002, Volume: 4, Issue:3

    Topics: Barrett Esophagus; Esomeprazole; Esophagitis; Female; Gastroesophageal Reflux; Humans; Omeprazole; Pregnancy; Pregnancy Complications; Proton Pump Inhibitors; Treatment Outcome

2002
Review article: esomeprazole in the treatment of Helicobacter pylori.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16 Suppl 4

    Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors

2002
Esomeprazole: a review of its use in the management of acid-related disorders.
    Drugs, 2002, Volume: 62, Issue:10

    Topics: Databases, Bibliographic; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome

2002
Esomeprazole magnesium (Nexium).
    Reviews in gastroenterological disorders, 2001, Volume: 1, Issue:1

    Topics: Anti-Ulcer Agents; Esomeprazole; Esophagitis; Gastroesophageal Reflux; Helicobacter Infections; Humans; Omeprazole; Treatment Outcome

2001
Esomeprazole: a clinical review.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2002, Jul-15, Volume: 59, Issue:14

    Topics: Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Esophagitis, Peptic; Helicobacter Infections; Humans; Omeprazole; Stereoisomerism

2002
Esomeprazole: update and clinical review.
    Reviews in gastroenterological disorders, 2002,Fall, Volume: 2, Issue:4

    Topics: Anti-Ulcer Agents; Clinical Trials as Topic; Drug Labeling; Enzyme Inhibitors; Esomeprazole; Esophagitis; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors

2002
Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
    Drugs, 2003, Volume: 63, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Dose-Response Relationship, Drug; Esomeprazole; Gastroesophageal Reflux; Helicobacter Infections; Humans; Omeprazole; Pantoprazole; Peptic Ulcer; Sulfoxides; Zollinger-Ellison Syndrome

2003
Review of esomeprazole in the treatment of acid disorders.
    Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:2

    Topics: Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esomeprazole; Esophagitis, Peptic; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic

2003
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.
    Nature reviews. Drug discovery, 2003, Volume: 2, Issue:2

    Topics: Animals; Clinical Trials as Topic; Enzyme Inhibitors; Esomeprazole; Humans; Omeprazole; Proton Pump Inhibitors; Stereoisomerism

2003
Review article: esomeprazole--the first proton pump inhibitor to be developed as an isomer.
    Alimentary pharmacology & therapeutics, 2003, Volume: 17 Suppl 1

    Topics: Drug Design; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Humans; Isomerism; Omeprazole; Proton Pump Inhibitors

2003
Review article: pharmacology of esomeprazole and comparisons with omeprazole.
    Alimentary pharmacology & therapeutics, 2003, Volume: 17 Suppl 1

    Topics: Anti-Ulcer Agents; Esomeprazole; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Omeprazole; Pentagastrin; Proton Pump Inhibitors

2003
Review article: initial therapy of reflux disease with esomeprazole.
    Alimentary pharmacology & therapeutics, 2003, Volume: 17 Suppl 1

    Topics: Anti-Ulcer Agents; Double-Blind Method; Esomeprazole; Gastroesophageal Reflux; Gastroscopy; Humans; Omeprazole; Randomized Controlled Trials as Topic

2003
Review article: Esomeprazole--enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion.
    Alimentary pharmacology & therapeutics, 2003, Feb-15, Volume: 17, Issue:4

    Topics: Anti-Ulcer Agents; Biological Availability; Esomeprazole; Gastric Acid; Humans; Omeprazole; Proton Pump Inhibitors

2003
On-demand proton pump inhibitor therapy in patients with gastro-oesophageal reflux disease.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2002, Volume: 34, Issue:12

    Topics: Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Ranitidine

2002
Synthesis or rupture: duration of acid inhibition by proton pump inhibitors.
    Drugs of today (Barcelona, Spain : 1998), 2003, Volume: 39 Suppl A

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Humans; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Time Factors

2003
[All proton pump inhibitors are equally efficacious in standard dosages].
    Lakartidningen, 2003, Jun-19, Volume: 100, Issue:25

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides

2003
Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication.
    Alimentary pharmacology & therapeutics, 2003, Sep-15, Volume: 18, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Esomeprazole; Evaluation Studies as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Treatment Outcome

2003
Single-isomer drugs: true therapeutic advances.
    Clinical pharmacokinetics, 2004, Volume: 43, Issue:5

    Topics: Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Stereoisomerism; Structure-Activity Relationship

2004
Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2004, Volume: 36, Issue:4

    Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Randomized Controlled Trials as Topic; Treatment Outcome

2004
[New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    Presse medicale (Paris, France : 1983), 2004, Jun-19, Volume: 33, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Esomeprazole; Gastric Acid; Humans; Liver; Metabolic Clearance Rate; Omeprazole; Parietal Cells, Gastric; Patient Selection; Peptic Ulcer; Polymorphism, Genetic; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Time Factors; Treatment Outcome

2004
Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
    The American journal of medicine, 2004, Sep-06, Volume: 117 Suppl 5A

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Satisfaction; Prognosis; Proton Pump Inhibitors; Risk Assessment; Severity of Illness Index; Treatment Outcome

2004
Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.
    Alimentary pharmacology & therapeutics, 2004, Volume: 20 Suppl 6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Wound Healing

2004
Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management.
    European journal of gastroenterology & hepatology, 2005, Volume: 17, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Pantoprazole; Prevalence; Proton Pump Inhibitors; Sulfoxides

2005
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
    Drug metabolism and pharmacokinetics, 2005, Volume: 20, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole

2005
What is potent acid inhibition, and how can it be achieved?
    Drugs, 2005, Volume: 65 Suppl 1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Esomeprazole; Gastric Acid; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides

2005
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
    European journal of clinical pharmacology, 2006, Volume: 62, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Muscular Diseases; Myositis; Omeprazole; Pantoprazole; Polymyositis; Proton Pump Inhibitors; Rabeprazole; Rhabdomyolysis

2006
A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori.
    Digestion, 2006, Volume: 73, Issue:2-3

    Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome

2006
Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
    Alimentary pharmacology & therapeutics, 2006, Sep-01, Volume: 24, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Enzyme Inhibitors; Esomeprazole; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome

2006
Pharmacokinetic drug interaction profiles of proton pump inhibitors.
    Drug safety, 2006, Volume: 29, Issue:9

    Topics: Anti-Ulcer Agents; Cytochrome P-450 CYP2D6; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Humans; Omeprazole; Proton Pump Inhibitors

2006
Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    International journal of clinical pharmacology and therapeutics, 2006, Volume: 44, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors

2006
[Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].
    Orvosi hetilap, 2007, Mar-25, Volume: 148, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole

2007
[Protonic pump inhibitors in kidney transplant patients: efficacy and safety].
    Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2007, Volume: 59, Issue:2

    Topics: Anti-Ulcer Agents; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Gastrointestinal Diseases; Humans; Kidney Transplantation; Omeprazole; Proton Pump Inhibitors; Proton Pumps; Treatment Outcome

2007
[Proton pump inhibitors in developmental period medicine].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2007, Volume: 22, Issue:128

    Topics: Adult; Age Factors; Anti-Ulcer Agents; Child; Drug Interactions; Duodenitis; Enzyme Inhibitors; Esomeprazole; Gastritis; Gastroesophageal Reflux; Helicobacter Infections; Humans; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors

2007
Recent advances in chirally pure proton pump inhibitors.
    Journal of the Indian Medical Association, 2007, Volume: 105, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esomeprazole; Gastroesophageal Reflux; Humans; Isomerism; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole

2007
Stereoselective disposition of proton pump inhibitors.
    Clinical drug investigation, 2008, Volume: 28, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Esomeprazole; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Stereoisomerism

2008
Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.
    Drugs, 2008, Volume: 68, Issue:11

    Topics: Adult; Anti-Ulcer Agents; Duodenal Ulcer; Esomeprazole; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Stomach Ulcer; Zollinger-Ellison Syndrome

2008
Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication.
    Alimentary pharmacology & therapeutics, 2008, Oct-01, Volume: 28, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Administration Schedule; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Pantoprazole; Proton Pump Inhibitors

2008
Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Helicobacter, 2008, Volume: 13, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Controlled Clinical Trials as Topic; Cytochrome P-450 CYP2C19; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Heterozygote; Homozygote; Humans; Lansoprazole; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole

2008
Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials.
    Alimentary pharmacology & therapeutics, 2009, Sep-15, Volume: 30, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esomeprazole; Esophagitis; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Treatment Outcome

2009
The pharmacology of esomeprazole and its role in gastric acid related diseases.
    Expert opinion on drug metabolism & toxicology, 2009, Volume: 5, Issue:9

    Topics: Clinical Trials as Topic; Drug Interactions; Esomeprazole; Gastrointestinal Diseases; Humans; Omeprazole

2009
Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Databases, Factual; Endoscopy, Gastrointestinal; Esomeprazole; Esophagitis; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Registries; Wound Healing

2010
Intravenous esomeprazole: a pharmacoeconomic profile of its use in the prevention of recurrent peptic ulcer bleeding.
    PharmacoEconomics, 2011, Volume: 29, Issue:6

    Topics: Anti-Ulcer Agents; Esomeprazole; Humans; Injections, Intravenous; Omeprazole; Peptic Ulcer Hemorrhage; Secondary Prevention

2011
[Interaction between clopidogrel and proton pump inhibitors].
    Nederlands tijdschrift voor geneeskunde, 2011, Volume: 155, Issue:28

    Topics: Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Gastrointestinal Hemorrhage; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine

2011
Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid.
    Expert review of gastroenterology & hepatology, 2011, Volume: 5, Issue:4

    Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Drug Therapy, Combination; Esomeprazole; Humans; Omeprazole; Peptic Ulcer; Randomized Controlled Trials as Topic; Risk

2011
Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review.
    Drug safety, 2012, Feb-01, Volume: 35, Issue:2

    Topics: Blood Platelets; Clopidogrel; Drug Interactions; Esomeprazole; Humans; Omeprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine

2012
The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis.
    PloS one, 2014, Volume: 9, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Magnesium; Odds Ratio; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Risk Factors; Treatment Outcome

2014
Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection.
    Journal of clinical pharmacy and therapeutics, 2015, Volume: 40, Issue:4

    Topics: Esomeprazole; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic

2015
Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis.
    International journal of clinical pharmacology and therapeutics, 2015, Volume: 53, Issue:10

    Topics: Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Publication Bias

2015
Association Between Proton Pump Inhibitors and Microscopic Colitis.
    The Annals of pharmacotherapy, 2017, Volume: 51, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Colitis, Microscopic; Dose-Response Relationship, Drug; Esomeprazole; Humans; Omeprazole; Pantoprazole; Practice Guidelines as Topic; Proton Pump Inhibitors

2017
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
    Medicine, 2017, Volume: 96, Issue:39

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Network Meta-Analysis; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; United States; United States Food and Drug Administration

2017
Recent Analytical Methodologies for the Determination of Omeprazole and/or Its Active Isomer Esomeprazole in Different Matrices: A Critical Review.
    Critical reviews in analytical chemistry, 2022, Volume: 52, Issue:1

    Topics: Electrochemical Techniques; Esomeprazole; Isomerism; Omeprazole; Stereoisomerism

2022
Pharmacologic treatment of GERD: Where we are now, and where are we going?
    Annals of the New York Academy of Sciences, 2020, Volume: 1482, Issue:1

    Topics: Cimetidine; Esomeprazole; Esophageal Mucosa; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Pyrroles; Sulfonamides

2020
Chiral separation in the class of proton pump inhibitors by chromatographic and electromigration techniques: An overview.
    Electrophoresis, 2021, Volume: 42, Issue:17-18

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Electrophoresis; Esomeprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole

2021
An update on drug-drug interactions associated with proton pump inhibitors.
    Expert opinion on drug metabolism & toxicology, 2022, Volume: 18, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Humans; Omeprazole; Prospective Studies; Proton Pump Inhibitors

2022
Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
    International journal of molecular sciences, 2022, 09-14, Volume: 23, Issue:18

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Antacids; Bone Density; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoporotic Fractures; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; United States

2022
Pharmacological treatment of gastro-oesophageal reflux in children.
    The Cochrane database of systematic reviews, 2023, 08-22, Volume: 8

    Topics: Adolescent; Child; Esomeprazole; Gastroesophageal Reflux; Humans; Infant; Infant, Newborn; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Ranitidine

2023

Trials

57 trial(s) available for omeprazole and s 1743

ArticleYear
Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease.
    Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:7

    Topics: Adult; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind Method; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Stereoisomerism

2000
Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators.
    Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:10

    Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Male; Middle Aged; Omeprazole

2000
One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease.
    Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:12

    Topics: Adult; Aged; Amoxicillin; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Stereoisomerism

2000
Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    The American journal of gastroenterology, 2001, Volume: 96, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biopsy, Needle; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Esomeprazole; Esophagitis; Female; Follow-Up Studies; Gastric Mucosa; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Probability; Reference Values; Secondary Prevention; Treatment Outcome

2001
Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months.
    Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:3

    Topics: Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Endoscopy; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Patient Satisfaction; Proton Pump Inhibitors; Stereoisomerism; Treatment Outcome

2001
Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
    The American journal of gastroenterology, 2001, Volume: 96, Issue:3

    Topics: Adult; Aged; Double-Blind Method; Enzyme Inhibitors; Esomeprazole; Esophagitis; Female; Gastroesophageal Reflux; Humans; Isomerism; Male; Middle Aged; Omeprazole; Safety; Treatment Outcome

2001
Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole.
    Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:10

    Topics: Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Cross-Over Studies; Esomeprazole; Gastric Acid; Gastric Acidity Determination; Gastrointestinal Agents; Humans; Male; Omeprazole; Pentagastrin; Proton Pump Inhibitors; Proton Pumps; Stereoisomerism; Time Factors

2001
One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease.
    European journal of gastroenterology & hepatology, 2001, Volume: 13, Issue:12

    Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Time Factors; Treatment Outcome

2001
Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease.
    Digestive diseases and sciences, 2002, Volume: 47, Issue:5

    Topics: Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Drug Tolerance; Esomeprazole; Female; Gastric Juice; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole

2002
Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months.
    European journal of gastroenterology & hepatology, 2002, Volume: 14, Issue:8

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Esomeprazole; Esophagoscopy; Female; Follow-Up Studies; Gastroesophageal Reflux; Gastroscopy; Humans; Long-Term Care; Male; Middle Aged; Omeprazole; Patient Satisfaction; Probability; Reference Values; Severity of Illness Index; Treatment Outcome

2002
[Esomeprazole in treating duodenal ulcer in various modes of anti-Helicobacter therapy].
    Terapevticheskii arkhiv, 2003, Volume: 75, Issue:2

    Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Humans; Male; Omeprazole

2003
One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease.
    Scandinavian journal of gastroenterology, 2003, Volume: 38, Issue:4

    Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Endoscopy, Gastrointestinal; Esomeprazole; Female; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Sensitivity and Specificity

2003
One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection.
    Alimentary pharmacology & therapeutics, 2003, Jun-01, Volume: 17, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Patient Compliance; Treatment Outcome

2003
Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance.
    Alimentary pharmacology & therapeutics, 2003, Oct-15, Volume: 18, Issue:8

    Topics: Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Patient Compliance; Treatment Outcome

2003
[Use of omeprazole and esomeprazole in patients suffering from bronchial asthma with associated gastroesophageal reflux disease].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2003, Issue:3

    Topics: Adult; Anti-Ulcer Agents; Asthma; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Time Factors; Treatment Outcome

2003
On-demand therapy for Los Angeles grade A and B reflux esophagitis: esomeprazole versus omeprazole.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2003, Volume: 102, Issue:9

    Topics: Anti-Ulcer Agents; Drug Administration Schedule; Esomeprazole; Esophagitis, Peptic; Female; Humans; Male; Middle Aged; Omeprazole; Treatment Outcome

2003
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    The American journal of gastroenterology, 2003, Volume: 98, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Chi-Square Distribution; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Least-Squares Analysis; Male; Middle Aged; Omeprazole; Pantoprazole; Rabeprazole; Sulfoxides; Treatment Outcome

2003
Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection.
    The American journal of gastroenterology, 2004, Volume: 99, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aluminum Hydroxide; Antacids; Breath Tests; Dose-Response Relationship, Drug; Drug Administration Schedule; Esomeprazole; Feces; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Reference Values; Single-Blind Method; Treatment Outcome; Urea

2004
Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study.
    Journal of clinical gastroenterology, 2004, Volume: 38, Issue:6

    Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Esomeprazole; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Pilot Projects; Probability; Prospective Studies; Reference Values; Treatment Outcome

2004
Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
    Alimentary pharmacology & therapeutics, 2004, Jul-01, Volume: 20, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Esomeprazole; False Negative Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Sulfoxides; Urea

2004
The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole.
    Alimentary pharmacology & therapeutics, 2004, Aug-15, Volume: 20, Issue:4

    Topics: Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Gastroscopy; Humans; Male; Middle Aged; Omeprazole; Treatment Outcome

2004
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    European journal of clinical pharmacology, 2004, Volume: 60, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Rabeprazole; Sulfoxides; Treatment Outcome

2004
A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects.
    European journal of clinical pharmacology, 2005, Volume: 60, Issue:11

    Topics: Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Cross-Over Studies; Esomeprazole; Female; Half-Life; Humans; Male; Omeprazole; Stereoisomerism; Time Factors

2005
Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
    Alimentary pharmacology & therapeutics, 2005, Feb-01, Volume: 21, Issue:3

    Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Chi-Square Distribution; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Follow-Up Studies; Gastric Mucosa; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Mixed Function Oxygenases; Omeprazole; Risk

2005
Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis.
    World journal of gastroenterology, 2005, May-28, Volume: 11, Issue:20

    Topics: Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Capsules; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Tablets

2005
[Comparison of esomeprazole- and omeprazole-based triple therapy regimens for duodenal ulcer with Helicobacter pylori infection].
    Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, 2005, Volume: 25, Issue:8

    Topics: Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole

2005
Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment?
    The American journal of gastroenterology, 2005, Volume: 100, Issue:9

    Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole

2005
Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
    Clinical pharmacology and therapeutics, 2005, Volume: 78, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Esomeprazole; Female; Gastroesophageal Reflux; Genotype; H(+)-K(+)-Exchanging ATPase; Half-Life; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Time Factors

2005
A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis.
    Digestive diseases and sciences, 2006, Volume: 51, Issue:5

    Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole

2006
[Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office].
    MMW Fortschritte der Medizin, 2005, Apr-07, Volume: 147 Suppl 1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Esomeprazole; Esophagitis, Peptic; Family Practice; Female; Germany; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pain Measurement; Patient Satisfaction; Prospective Studies; Proton Pump Inhibitors; Recurrence

2005
A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis.
    Digestive diseases and sciences, 2006, Volume: 51, Issue:5

    Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole

2006
Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.
    Alimentary pharmacology & therapeutics, 2006, Jul-15, Volume: 24, Issue:2

    Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cross-Over Studies; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Rifabutin; Treatment Outcome

2006
Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
    Alimentary pharmacology & therapeutics, 2007, Jan-15, Volume: 25, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Antacids; Anti-Ulcer Agents; Cross-Over Studies; Drug Administration Schedule; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Treatment Outcome

2007
One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole

2007
Effect of baseline symptom severity on patient-reported outcomes in gastroesophageal reflux disease.
    European journal of gastroenterology & hepatology, 2007, Volume: 19, Issue:7

    Topics: Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Ranitidine; Severity of Illness Index; Treatment Outcome

2007
Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects.
    International journal of clinical pharmacology and therapeutics, 2007, Volume: 45, Issue:6

    Topics: Adult; Anti-Ulcer Agents; Area Under Curve; Cross-Over Studies; Depression, Chemical; Dose-Response Relationship, Drug; Double-Blind Method; Esomeprazole; Female; Gastric Acid; Half-Life; Humans; Hydrogen-Ion Concentration; Injections, Intravenous; Male; Microelectrodes; Middle Aged; Omeprazole

2007
Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate.
    Helicobacter, 2007, Volume: 12, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole

2007
Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.
    Alimentary pharmacology & therapeutics, 2008, Volume: 28, Issue:2

    Topics: Adult; Anti-Ulcer Agents; Esomeprazole; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Male; Omeprazole; Proton Pump Inhibitors; Treatment Outcome

2008
A glass of water immediately increases gastric pH in healthy subjects.
    Digestive diseases and sciences, 2008, Volume: 53, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Cross-Over Studies; Esomeprazole; Female; Humans; Hydrogen-Ion Concentration; Male; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Ranitidine; Stomach; Time Factors; Water

2008
A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children.
    Acta paediatrica (Oslo, Norway : 1992), 2009, Volume: 98, Issue:1

    Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Clarithromycin; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Probiotics; Prospective Studies; Proton Pump Inhibitors; Saccharomyces

2009
Effect of proton pump inhibitors on gastric juice volume, gastric pH and gastric intramucosal pH in critically ill patients : a randomized, double-blind, placebo-controlled study.
    Clinical drug investigation, 2008, Volume: 28, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Critical Illness; Double-Blind Method; Esomeprazole; Female; Gastric Acidity Determination; Gastric Juice; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole

2008
Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
    World journal of gastroenterology, 2009, Feb-28, Volume: 15, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Patient Selection

2009
Seven-day intravenous low-dose omeprazole infusion reduces peptic ulcer rebleeding for patients with comorbidities.
    Gastrointestinal endoscopy, 2009, Volume: 70, Issue:3

    Topics: Aged; Aged, 80 and over; Comorbidity; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Duodenal Ulcer; Education, Medical, Continuing; Esomeprazole; Female; Follow-Up Studies; Hemostasis, Endoscopic; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Omeprazole; Peptic Ulcer Hemorrhage; Probability; Prospective Studies; Risk Assessment; Secondary Prevention; Severity of Illness Index; Statistics, Nonparametric; Stomach Ulcer; Survival Rate; Time Factors; Treatment Outcome

2009
Oral or intravenous proton pump inhibitor in patients with peptic ulcer bleeding after successful endoscopic epinephrine injection.
    British journal of clinical pharmacology, 2009, Volume: 67, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Endoscopy; Epinephrine; Esomeprazole; Female; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Secondary Prevention; Treatment Outcome; Young Adult

2009
[Omeprazol and ezomeprazol pharmacokinetics, duration of antisecretory effect, and reasons for their probable changes in duodenal ulcer].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2009, Issue:4

    Topics: Adult; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; Esomeprazole; Female; Gastric Acid; Gastric Acidity Determination; Humans; Male; Omeprazole; Proton Pump Inhibitors; Time Factors; Tissue Distribution

2009
Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting.
    Journal of cardiovascular pharmacology, 2010, Volume: 56, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Esomeprazole; Female; Humans; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Regression Analysis; Stents; Ticlopidine

2010
Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping.
    Alimentary pharmacology & therapeutics, 2011, Volume: 33, Issue:4

    Topics: Adolescent; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drugs, Generic; Enzyme Inhibitors; Esomeprazole; Female; Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Statistics as Topic; White People; Young Adult

2011
A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    Journal of the American College of Cardiology, 2012, Apr-03, Volume: 59, Issue:14

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Blood Coagulation; Blood Platelets; Clopidogrel; Confidence Intervals; Cross-Over Studies; Dexlansoprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Reference Values; Ticlopidine; Young Adult

2012
Effect of intravenous proton pump inhibitor regimens and timing of endoscopy on clinical outcomes of peptic ulcer bleeding.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:9

    Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Blood Transfusion; Chi-Square Distribution; Double-Blind Method; Endoscopy, Gastrointestinal; Esomeprazole; Female; Hemostasis, Endoscopic; Humans; Length of Stay; Male; Middle Aged; Omeprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Risk Factors; Secondary Prevention; Time Factors

2012
[Efficacy of esomeprazole compared with omeprazole in reflux esophagitis patients -a phase III, multicenter, randomized, double-blind, parallel-group trial-].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2013, Volume: 110, Issue:2

    Topics: Aged; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors

2013
[Efficacy and safety of esomeprazole, compared with omeprazole, in maintenance therapy for reflux esophagitis -a phase III, multicenter, randomized, double-blind trial-].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2013, Volume: 110, Issue:8

    Topics: Aged; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors

2013
Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:9

    Topics: Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Esomeprazole; Female; Gastric Acid; Genotype; Humans; Hydrogen-Ion Concentration; Japan; Lansoprazole; Male; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Young Adult

2013
Effect of esomeprazole with/without acetylsalicylic acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:3

    Topics: Adolescent; Adult; Area Under Curve; Aspirin; Clopidogrel; Cross-Over Studies; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Healthy Volunteers; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Platelet Aggregation; Proton Pump Inhibitors; Ticlopidine; Young Adult

2014
Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software.
    Alzheimer's research & therapy, 2015, Dec-27, Volume: 7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cognition; Esomeprazole; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Software; Young Adult

2015
Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
    Journal of breath research, 2016, Jan-27, Volume: 10, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Blood Platelets; Breath Tests; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Esomeprazole; Humans; Omeprazole; Pantoprazole; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Proton Pump Inhibitors; Ranitidine; Ticlopidine

2016
The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole-
    Journal of breath research, 2016, 12-17, Volume: 10, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Biomarkers; Breath Tests; Carbon Radioisotopes; Cytochrome P-450 CYP2C19; Esomeprazole; Female; Gastroesophageal Reflux; Genetic Association Studies; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Pharmacogenetics; Precision Medicine; Proton Pump Inhibitors; Young Adult

2016
Omeprazole Administration in Preterm Preeclampsia: a Randomized Controlled Trial to Study Its Effect on sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1), PlGF (Placental Growth Factor), and ET-1 (Endothelin-1).
    Hypertension (Dallas, Tex. : 1979), 2022, Volume: 79, Issue:6

    Topics: Adult; Biomarkers; Endothelin-1; Esomeprazole; Female; Humans; Infant; Infant, Newborn; Omeprazole; Placenta; Placenta Growth Factor; Pre-Eclampsia; Pregnancy; Proton Pump Inhibitors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1

2022

Other Studies

100 other study(ies) available for omeprazole and s 1743

ArticleYear
Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
    Scandinavian journal of gastroenterology. Supplement, 2001, Issue:234

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esomeprazole; Half-Life; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Parietal Cells, Gastric; Prodrugs; Proton Pump Inhibitors; Rabeprazole; Sulfoxides

2001
Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies.
    PharmacoEconomics, 2002, Volume: 20, Issue:4

    Topics: Adult; Cost-Benefit Analysis; Enzyme Inhibitors; Esomeprazole; Esophagitis; Female; Gastroesophageal Reflux; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Omeprazole; Proton Pump Inhibitors; United Kingdom

2002
Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK.
    PharmacoEconomics, 2002, Volume: 20, Issue:4

    Topics: Anti-Ulcer Agents; Cost-Benefit Analysis; Decision Support Techniques; Esomeprazole; Esophagitis, Peptic; Female; Humans; Male; Middle Aged; Omeprazole; United Kingdom

2002
Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Drugs, 2002, Volume: 62, Issue:7

    Topics: Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors

2002
Proton pump inhibitors: an update.
    American family physician, 2002, Jul-15, Volume: 66, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Interactions; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides

2002
[Pharma clinics medication of the month. Esomeprazole].
    Revue medicale de Liege, 2002, Volume: 57, Issue:9

    Topics: Cost Control; Drug Costs; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Helicobacter Infections; Humans; Omeprazole; Proton Pump Inhibitors

2002
Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori.
    The Journal of antimicrobial chemotherapy, 2003, Volume: 51, Issue:2

    Topics: Adult; Anti-Ulcer Agents; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole

2003
Prilosec, nexium and stereoisomers.
    The Medical letter on drugs and therapeutics, 2003, Jun-23, Volume: 45, Issue:1159

    Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug Interactions; Esomeprazole; Methylphenidate; Omeprazole; Proton Pump Inhibitors; Stereoisomerism

2003
Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2004, Volume: 21, Issue:2-3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost Control; Cost-Benefit Analysis; Databases, Factual; Decision Trees; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Models, Economic; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome

2004
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Drug metabolism and disposition: the biological fate of chemicals, 2004, Volume: 32, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Sulfoxides

2004
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
    Journal of the National Cancer Institute, 2004, Nov-17, Volume: 96, Issue:22

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Animals; Antineoplastic Agents; Benzimidazoles; Blotting, Western; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Esomeprazole; Fluorouracil; Humans; Hydrogen-Ion Concentration; Immunohistochemistry; Inhibitory Concentration 50; Lymphoma; Melanoma; Mice; Mice, SCID; Microscopy, Confocal; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Transplantation, Heterologous; Vinblastine

2004
[Gastroesophageal reflux disease refractory to esomeprazole].
    Gastroenterologia y hepatologia, 2005, Volume: 28, Issue:2

    Topics: Adult; Anti-Ulcer Agents; Esomeprazole; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Omeprazole; Proton Pump Inhibitors; Treatment Failure

2005
Comparative study and optimisation of the administration mode of three proton pump inhibitors by nasogastric tube.
    International journal of pharmaceutics, 2005, Aug-11, Volume: 299, Issue:1-2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Beverages; Esomeprazole; Intubation, Gastrointestinal; Lansoprazole; Malus; Omeprazole; Particle Size; Polyurethanes; Proton Pump Inhibitors; Rheology; Silicones; Solvents; Water

2005
Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
    The Laryngoscope, 2005, Volume: 115, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cohort Studies; Drug Administration Schedule; Enzyme Inhibitors; Esomeprazole; Female; Fiber Optic Technology; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Hypopharynx; Lansoprazole; Laryngoscopy; Male; Manometry; Middle Aged; Omeprazole; Predictive Value of Tests; Prospective Studies; Proton Pump Inhibitors; Severity of Illness Index; Surveys and Questionnaires; Time Factors

2005
Long-term omeprazole and esomeprazole treatment does not significantly increase gastric epithelial cell proliferation and epithelial growth factor receptor expression and has no effect on apoptosis and p53 expression.
    World journal of gastroenterology, 2005, Aug-14, Volume: 11, Issue:30

    Topics: Adult; Apoptosis; Cell Proliferation; Epithelial Cells; ErbB Receptors; Esomeprazole; Female; Gastric Mucosa; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Tumor Suppressor Protein p53

2005
Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
    Current medical research and opinion, 2005, Volume: 21, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; United Kingdom

2005
Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2006, Feb-02, Volume: 831, Issue:1-2

    Topics: Chromatography, High Pressure Liquid; Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization

2006
Determination of esomeprazole and its two main metabolites in human, rat and dog plasma by liquid chromatography with tandem mass spectrometry.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007, Apr-01, Volume: 848, Issue:2

    Topics: Animals; Calibration; Chromatography, Liquid; Dogs; Esomeprazole; Humans; Molecular Structure; Omeprazole; Rats; Reproducibility of Results; Tandem Mass Spectrometry

2007
An in vitro comparison of different providers to deliver four proton pump inhibitor products through a feeding tube.
    Alimentary pharmacology & therapeutics, 2006, Volume: 24, Issue:11-12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Esomeprazole; Female; Humans; Infusions, Parenteral; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Satisfaction; Proton Pump Inhibitors; Proton Pumps

2006
Severe systemic adverse reaction to proton pump inhibitors in an infant.
    Pediatric pulmonology, 2007, Volume: 42, Issue:6

    Topics: Enzyme Inhibitors; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Infant; Lung Diseases; Omeprazole; Proton Pump Inhibitors; Respiratory Sounds

2007
The anti-secretory and anti-ulcer activities of esomeprazole in comparison with omeprazole in the stomach of rats and rabbits.
    Molecular and cellular biochemistry, 2008, Volume: 309, Issue:1-2

    Topics: Aminopyrine; Animals; Anti-Ulcer Agents; Bucladesine; Carbon Isotopes; Dimaprit; Dinoprostone; Esomeprazole; Female; Gastric Acid; Gastric Mucosa; Histamine; Indomethacin; Inhibitory Concentration 50; Male; Omeprazole; Rabbits; Rats; Rats, Wistar; Stomach

2008
Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England.
    Drug safety, 2008, Volume: 31, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Cohort Studies; Diarrhea; Drug Monitoring; Dyspepsia; England; Esomeprazole; Esophageal Diseases; Female; Humans; Male; Middle Aged; Omeprazole; Primary Health Care; Product Surveillance, Postmarketing; Proton Pump Inhibitors

2008
[General practitioners' management of gastroesophageal reflux in France in 2005: a pharmacoeconomic study].
    Presse medicale (Paris, France : 1983), 2008, Volume: 37, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Costs and Cost Analysis; Esomeprazole; Family Practice; Female; France; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pumps; Rabeprazole

2008
Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials.
    Drug safety, 2008, Volume: 31, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Community-Acquired Infections; Esomeprazole; Female; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Retrospective Studies; Young Adult

2008
[Chronic use of proton-pump inhibitors associated with giardiasis: A rare cause of hypomagnesemic hypoparathyroidism?].
    Annales d'endocrinologie, 2008, Volume: 69, Issue:5

    Topics: Deglutition Disorders; Duodenum; Esomeprazole; Female; Giardiasis; Humans; Hypocalcemia; Hypoparathyroidism; Magnesium Deficiency; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quadriplegia; Vomiting

2008
Physical and chemical stability of esomeprazole sodium solutions.
    The Annals of pharmacotherapy, 2008, Volume: 42, Issue:9

    Topics: Anti-Ulcer Agents; Drug Stability; Drug Storage; Esomeprazole; Glucose; Humans; Isotonic Solutions; Omeprazole; Polyvinyl Chloride; Ringer's Lactate; Sodium Chloride; Solutions; Time Factors

2008
Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease.
    European journal of clinical pharmacology, 2009, Volume: 65, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Clinical Trials as Topic; Databases, Bibliographic; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Utilization Review; Esomeprazole; European Union; Gastroesophageal Reflux; Government Agencies; Humans; Isomerism; Lansoprazole; Multicenter Studies as Topic; Omeprazole; Pediatrics; Proton Pump Inhibitors; United States; United States Food and Drug Administration

2009
Transmucosal gastric leak induced by proton pump inhibitors.
    Digestive diseases and sciences, 2009, Volume: 54, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Epithelium; Esomeprazole; Gastric Mucosa; Hydrogen-Ion Concentration; In Vitro Techniques; Lansoprazole; Male; Omeprazole; Permeability; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley

2009
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2008, Volume: 52, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Data Interpretation, Statistical; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole

2008
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.
    American heart journal, 2009, Volume: 157, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Blood Platelets; Clopidogrel; Drug Interactions; Esomeprazole; Female; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine

2009
Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
    Journal of clinical pharmacy and therapeutics, 2009, Volume: 34, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Color; Drug Incompatibility; Drug Stability; Drug Storage; Esomeprazole; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Nefopam; Omeprazole; Pantoprazole; Pharmaceutical Solutions; Proton Pump Inhibitors; Temperature; Time Factors

2009
Microscopic colitis associated with omeprazole and esomeprazole exposure.
    Journal of clinical gastroenterology, 2009, Volume: 43, Issue:6

    Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Colitis, Microscopic; Dose-Response Relationship, Drug; Esomeprazole; Female; Humans; Male; Middle Aged; Omeprazole

2009
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Proton Pump Inhibitors; Stents; Ticlopidine

2009
Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease: an observational, multicentre study.
    Clinical drug investigation, 2009, Volume: 29, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Netherlands; Omeprazole; Patient Satisfaction; Primary Health Care; Proton Pump Inhibitors; Surveys and Questionnaires; Young Adult

2009
Direct HPLC enantioseparation of omeprazole and its chiral impurities: application to the determination of enantiomeric purity of esomeprazole magnesium trihydrate.
    Journal of pharmaceutical and biomedical analysis, 2010, Sep-05, Volume: 52, Issue:5

    Topics: Chromatography, High Pressure Liquid; Circular Dichroism; Esomeprazole; Limit of Detection; Omeprazole; Reference Standards; Reproducibility of Results; Spectrophotometry, Ultraviolet; Stereoisomerism

2010
[Comparative study of esomeprazole and omeprazole using for initialism therapy for elderly-senile and young-adulthood patients with GERD].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2009, Issue:7

    Topics: Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole

2009
Nonpigmented fixed drug eruption induced by esomeprazole.
    Cutaneous and ocular toxicology, 2010, Volume: 29, Issue:3

    Topics: Drug Eruptions; Esomeprazole; Esophagitis, Peptic; Female; Humans; Middle Aged; Omeprazole; Proton Pump Inhibitors; Skin Pigmentation; Treatment Outcome

2010
Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice.
    Journal of gastrointestinal and liver diseases : JGLD, 2010, Volume: 19, Issue:2

    Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Male; Medication Adherence; Middle Aged; Ofloxacin; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors; Rifabutin; Time Factors; Treatment Failure

2010
Racemization of the gastrointestinal antisecretory chiral drug esomeprazole magnesium via the pyramidal inversion mechanism: A theoretical study.
    Chirality, 2010, Volume: 22, Issue:9

    Topics: Anti-Ulcer Agents; Esomeprazole; Gastrointestinal Tract; Models, Molecular; Molecular Conformation; Omeprazole; Quantum Theory; Stereoisomerism; Temperature; Thermodynamics

2010
Esomeprazole for the treatment of peptic ulcer bleeding.
    Expert review of gastroenterology & hepatology, 2010, Volume: 4, Issue:6

    Topics: Administration, Oral; Dose-Response Relationship, Drug; Esomeprazole; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Omeprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Treatment Outcome

2010
Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
    Journal of managed care pharmacy : JMCP, 2011, Volume: 17, Issue:3

    Topics: Arkansas; Cost Savings; Cost Sharing; Databases, Factual; Drug Costs; Drug Utilization Review; Esomeprazole; Health Benefit Plans, Employee; Health Expenditures; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Longitudinal Studies; Nonprescription Drugs; Omeprazole; Organizational Policy; Proton Pump Inhibitors; State Government

2011
Influence of esomeprazole on hypoglycemic activity of oral antidiabetic agents in rats and rabbits.
    Molecular and cellular biochemistry, 2011, Volume: 354, Issue:1-2

    Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Drug Evaluation, Preclinical; Drug Therapy, Combination; Enzyme Assays; Esomeprazole; Female; Glucose Oxidase; Hypoglycemic Agents; Insulin; Male; Omeprazole; Peroxidase; Rabbits; Rats; Sulfonylurea Compounds

2011
Effects of different proton pump inhibitors on cardiac contractility in isolated human failing myocardium.
    The Journal of cardiovascular surgery, 2011, Volume: 52, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Esomeprazole; Heart Failure; Heart Ventricles; Humans; In Vitro Techniques; Kinetics; Myocardial Contraction; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Ventricular Function, Right

2011
Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
    Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Esomeprazole; Esophagitis, Peptic; Faith Healing; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Logistic Models; Los Angeles; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Racial Groups; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Young Adult

2011
Whole-cell oxidation of omeprazole sulfide to enantiopure esomeprazole with Lysinibacillus sp. B71.
    Bioresource technology, 2011, Volume: 102, Issue:17

    Topics: Bacillus; Base Sequence; Bioreactors; Biotransformation; Chromatography, Thin Layer; Culture Media; DNA Primers; Esomeprazole; Hydrogen-Ion Concentration; Omeprazole; Oxidation-Reduction; Polymerase Chain Reaction; Stereoisomerism; Temperature

2011
The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Inhibitory Concentration 50; Lansoprazole; Microsomes; Microsomes, Liver; Omeprazole; Pantoprazole; Protein Binding; Proton Pump Inhibitors; Recombinant Proteins; Ticlopidine

2011
Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention.
    Vascular health and risk management, 2011, Volume: 7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Asian; Asian People; Blood Platelets; China; Clopidogrel; Drug Resistance; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; New York City; Omeprazole; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Stents; Thrombosis; Ticlopidine; Time Factors

2011
Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
    Pharmacoepidemiology and drug safety, 2011, Volume: 20, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Databases, Factual; Drug Interactions; Esomeprazole; Female; Herb-Drug Interactions; Hospitalization; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Recurrence; Retrospective Studies; Ticlopidine; Treatment Outcome

2011
The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon.
    British journal of clinical pharmacology, 2012, Volume: 74, Issue:6

    Topics: Age Factors; Algorithms; Anti-Ulcer Agents; Anticoagulants; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Male; Omeprazole; Phenprocoumon; Predictive Value of Tests; Vitamin K

2012
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cells, Cultured; Computer Simulation; Cytochrome P-450 CYP2C19; Dealkylation; Dexlansoprazole; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Kinetics; Lansoprazole; Liver; Microsomes, Liver; Models, Biological; NADP; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Recombinant Proteins; Substrate Specificity

2012
Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System.
    International journal of medical sciences, 2012, Volume: 9, Issue:5

    Topics: Adverse Drug Reaction Reporting Systems; Data Mining; Enzyme Inhibitors; Esomeprazole; Humans; Hypercalciuria; Nephrocalcinosis; Omeprazole; Renal Tubular Transport, Inborn Errors; United States; United States Food and Drug Administration

2012
Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Alimentary pharmacology & therapeutics, 2012, Volume: 36, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Esomeprazole; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Time Factors; Treatment Outcome

2012
A positive event dependence model for self-controlled case series with applications in postmarketing surveillance.
    Biometrics, 2013, Volume: 69, Issue:1

    Topics: Computer Simulation; Esomeprazole; Humans; Lactones; Models, Statistical; Myocardial Infarction; Omeprazole; Product Surveillance, Postmarketing; Research Design; Sulfones

2013
Cutaneous reactions to proton pump inhibitors: a case-control study.
    Journal of drugs in dermatology : JDD, 2012, Volume: 11, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Angioedema; Case-Control Studies; Chi-Square Distribution; Drug Eruptions; Esomeprazole; Exanthema; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Prevalence; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Statistics, Nonparametric; Stevens-Johnson Syndrome; Thailand; Urticaria; Young Adult

2012
Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients.
    Current medical research and opinion, 2013, Volume: 29, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Myocardial Infarction; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Risk; Stroke; Ticlopidine

2013
Subacute cutaneous lupus erythematosus induced and exacerbated by proton pump inhibitors.
    Dermatology (Basel, Switzerland), 2013, Volume: 226, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Esomeprazole; Female; Humans; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors

2013
Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome.
    Pancreas, 2013, Volume: 42, Issue:6

    Topics: Achlorhydria; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; False Positive Reactions; Female; Gastric Acid; Gastric Mucosa; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Rabeprazole; Secretin; Sensitivity and Specificity; Stomach; Young Adult; Zollinger-Ellison Syndrome

2013
Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study.
    Scandinavian journal of gastroenterology, 2013, Volume: 48, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Substitution; Esomeprazole; Gastroesophageal Reflux; Health Policy; Humans; Insurance, Health, Reimbursement; Lansoprazole; Norway; Omeprazole; Pantoprazole; Proton Pump Inhibitors

2013
Relaxant effect of proton pump inhibitors on in vitro myometrium from pregnant women.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2014, Feb-14, Volume: 52

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Apamin; Calcium; Dinoprostone; Esomeprazole; Female; Humans; In Vitro Techniques; Indomethacin; Lansoprazole; Muscle Contraction; Myometrium; NG-Nitroarginine Methyl Ester; Omeprazole; Oxytocin; Pantoprazole; Peptides; Potassium Chloride; Pregnancy; Proton Pump Inhibitors; Rabeprazole; Tocolytic Agents

2014
[Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2014, Volume: 63, Issue:2

    Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Logistic Models; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Retrospective Studies; Treatment Outcome

2014
Human P450-like oxidation of diverse proton pump inhibitor drugs by 'gatekeeper' mutants of flavocytochrome P450 BM3.
    The Biochemical journal, 2014, Jun-01, Volume: 460, Issue:2

    Topics: Bacillus megaterium; Bacterial Proteins; Crystallography, X-Ray; Cytochrome P-450 Enzyme System; Esomeprazole; Humans; NADPH-Ferrihemoprotein Reductase; Nuclear Magnetic Resonance, Biomolecular; Omeprazole; Oxidation-Reduction; Proton Pump Inhibitors; Substrate Specificity

2014
Single enantiomer versus racemate: chiral distinction in the proton pump inhibitors omeprazole and esomeprazole.
    Chirality, 2014, Volume: 26, Issue:4

    Topics: Dimerization; Esomeprazole; Humans; Models, Chemical; Models, Molecular; Omeprazole; Proton Pump Inhibitors; Stereoisomerism; Water

2014
The clopidogrel conundrum.
    Journal of clinical pharmacology, 2014, Volume: 54, Issue:8

    Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Drug Interactions; Esomeprazole; Genotype; Humans; Omeprazole; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Proton Pump Inhibitors; Ticlopidine; Treatment Outcome

2014
Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
    Stroke, 2015, Volume: 46, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Data Interpretation, Statistical; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proportional Hazards Models; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Risk; Stroke; Ticlopidine

2015
In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
    International journal of pharmaceutics, 2015, May-15, Volume: 485, Issue:1-2

    Topics: Age Factors; Bicarbonates; Buffers; Chemistry, Pharmaceutical; Esomeprazole; Geriatrics; Humans; Hydrogen-Ion Concentration; Kinetics; Lansoprazole; Omeprazole; Particle Size; Pediatrics; Phosphates; Proton Pump Inhibitors; Sodium Chloride; Solubility; Tablets, Enteric-Coated; Technology, Pharmaceutical

2015
Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies.
    Alimentary pharmacology & therapeutics, 2015, Volume: 41, Issue:11

    Topics: Aged; Chromogranin A; Esomeprazole; Female; Gastrins; Gastroesophageal Reflux; Humans; Laparoscopy; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Young Adult

2015
Development and validation of a DESI-HRMS/MS method for the fast profiling of esomeprazole and its metabolites in rat plasma: a pharmacokinetic study.
    Drug testing and analysis, 2016, Volume: 8, Issue:2

    Topics: Animals; Area Under Curve; Biotransformation; Chromatography, High Pressure Liquid; Esomeprazole; Limit of Detection; Liquid-Liquid Extraction; Male; Omeprazole; Proton Pump Inhibitors; Rats; Rats, Wistar; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry

2016
In vitro study of the variable effects of proton pump inhibitors on voriconazole.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antifungal Agents; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Esomeprazole; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Voriconazole

2015
Letter: proton pump inhibitors, hypergastrinaemia and the risk of gastric neoplasia.
    Alimentary pharmacology & therapeutics, 2015, Volume: 42, Issue:3

    Topics: Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Omeprazole; Proton Pump Inhibitors

2015
CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine.
    The Journal of pharmacology and experimental therapeutics, 2015, Volume: 354, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Cytochrome P-450 CYP2C19; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Female; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Precision Medicine; Proton Pump Inhibitors; Reproducibility of Results; Young Adult

2015
Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon.
    European journal of clinical pharmacology, 2015, Volume: 71, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acenocoumarol; Aged; Aged, 80 and over; Anti-Ulcer Agents; Anticoagulants; Dose-Response Relationship, Drug; Drug Interactions; Esomeprazole; Female; Hospitalization; Hospitals, Teaching; Humans; International Normalized Ratio; Male; Omeprazole; Pantoprazole; Phenprocoumon

2015
Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch.
    Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2015, Nov-14, Volume: 23

    Topics: Esomeprazole; Gastroesophageal Reflux; Helicobacter Infections; Humans; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Stereoisomerism

2015
Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period.
    Alimentary pharmacology & therapeutics, 2016, Volume: 44, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult

2016
Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance.
    Cell death & disease, 2016, 07-21, Volume: 7

    Topics: Animals; Cryopyrin-Associated Periodic Syndromes; Esomeprazole; Gene Expression Regulation; Humans; Interleukin-1beta; Lipopolysaccharides; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Monocytes; Omeprazole; Peritonitis; Primary Cell Culture; Proton Pump Inhibitors; Shock, Septic; Signal Transduction; Survival Analysis; Thioglycolates; Toll-Like Receptors; Tumor Necrosis Factor-alpha; Zymosan

2016
Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
    Gastroenterology, 2017, Volume: 152, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administrative Claims, Healthcare; Adult; Aged; Case-Control Studies; Esomeprazole; Female; Hepatic Encephalopathy; Humans; Incidence; Insurance, Health; Lansoprazole; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Taiwan

2017
Proton pump inhibitors, purple gastric juice and peptic ulcer disease.
    QJM : monthly journal of the Association of Physicians, 2017, Volume: 110, Issue:1

    Topics: Aged, 80 and over; Endoscopy, Digestive System; Esomeprazole; Female; Gastric Juice; Humans; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors

2017
Influences of proton pump inhibitor on Helicobacter pylori adherence to the gastrointestinal cell lines.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2017, Volume: 28, Issue:1

    Topics: Antibiotics, Antitubercular; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bacterial Adhesion; Caco-2 Cells; Esomeprazole; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Rifampin; Time Factors

2017
Effect of baseline characteristics on response to proton pump inhibitors in patients with peptic ulcer bleeding.
    Journal of digestive diseases, 2017, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Asian People; China; Esomeprazole; Europe; Female; Health Status; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Secondary Prevention; Severity of Illness Index; Treatment Outcome; White People

2017
Drug interaction: Clopidogrel and PPIs.
    The Medical letter on drugs and therapeutics, 2017, 02-27, Volume: 59, Issue:1515

    Topics: Clopidogrel; Drug Interactions; Esomeprazole; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk Factors; Ticlopidine

2017
High performance liquid chromatography with photo diode array for separation and analysis of naproxen and esomeprazole in presence of their chiral impurities: Enantiomeric purity determination in tablets.
    Journal of chromatography. A, 2017, May-12, Volume: 1497

    Topics: 2-Propanol; Chromatography, High Pressure Liquid; Esomeprazole; Hexanes; Limit of Detection; Naproxen; Omeprazole; Reproducibility of Results; Stereoisomerism; Tablets; Trifluoroacetic Acid

2017
Omeprazole-induced hallucinations. Not as rare as you might think.
    Gastroenterologia y hepatologia, 2018, Volume: 41, Issue:4

    Topics: Adult; Drug Substitution; Esomeprazole; Esophagitis, Peptic; Hallucinations; Hernia, Hiatal; Humans; Male; Omeprazole; Proton Pump Inhibitors

2018
A pilot study comparing the effect of orally administered esomeprazole and omeprazole on gastric fluid pH in horses.
    New Zealand veterinary journal, 2017, Volume: 65, Issue:6

    Topics: Animals; Anti-Ulcer Agents; Esomeprazole; Horse Diseases; Horses; Hydrogen-Ion Concentration; Omeprazole; Pilot Projects; Random Allocation; Treatment Outcome

2017
Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study).
    Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Asian People; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Outpatients; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Time Factors; Treatment Outcome; Young Adult

2018
Proton pump inhibitor as an independent factor of progression of abdominal aortic calcification in patients on maintenance hemodialysis.
    PloS one, 2018, Volume: 13, Issue:7

    Topics: Aged; Aorta, Abdominal; Computed Tomography Angiography; Disease Progression; Esomeprazole; Female; Humans; Kidney Failure, Chronic; Lansoprazole; Logistic Models; Magnesium; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Renal Dialysis; Retrospective Studies; Vascular Calcification

2018
Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study.
    European journal of internal medicine, 2019, Volume: 59

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Esomeprazole; Female; Hospitalization; Humans; Hyponatremia; Lansoprazole; Logistic Models; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Population; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Sweden; Young Adult

2019
A potential risk factor for paraoxonase 1: in silico and in-vitro analysis of the biological activity of proton-pump inhibitors.
    The Journal of pharmacy and pharmacology, 2019, Volume: 71, Issue:10

    Topics: Aryldialkylphosphatase; Enzyme Inhibitors; Esomeprazole; Humans; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Risk Factors

2019
Qualimetric analysis of proton pump inhibitors in Ukraine.
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2019, Volume: 72, Issue:9 cz 2

    Topics: Dexlansoprazole; Esomeprazole; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Quality Control; Rabeprazole; Ukraine

2019
Ultra high performance liquid chromatography method development for separation of omeprazole and related substances on core-shell columns using a Quality by Design approach.
    Journal of separation science, 2020, Volume: 43, Issue:4

    Topics: Chromatography, High Pressure Liquid; Esomeprazole; Omeprazole; Temperature

2020
A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations.
    British journal of clinical pharmacology, 2020, Volume: 86, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Humans; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Voriconazole

2020
Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
    Pharmacology, 2020, Volume: 105, Issue:11-12

    Topics: Antioxidants; Ascorbic Acid; Biphenyl Compounds; Esomeprazole; Free Radicals; In Vitro Techniques; Inhibitory Concentration 50; Lansoprazole; Omeprazole; Pantoprazole; Picrates; Proton Pump Inhibitors; Rabeprazole; Spectrophotometry

2020
Esomeprazole inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis.
    Investigational new drugs, 2021, Volume: 39, Issue:2

    Topics: Animals; Anti-Ulcer Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cysteine Endopeptidases; Cysteine Proteases; Esomeprazole; Female; Humans; Lung Neoplasms; Lysosomes; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Omeprazole; Xenograft Model Antitumor Assays

2021
Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use.
    Drug design, development and therapy, 2020, Volume: 14

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drugs, Investigational; Esomeprazole; Humans; Lansoprazole; Molecular Structure; Omeprazole; Pantoprazole; Polypropylenes; Proton Pump Inhibitors; Rabeprazole

2020
Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics.
    CPT: pharmacometrics & systems pharmacology, 2022, Volume: 11, Issue:1

    Topics: Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Down-Regulation; Drug Interactions; Esomeprazole; Humans; Inflammation; Interleukin-6; Midazolam; Omeprazole

2022
Proton pump inhibitor therapy and risk of knee replacement surgery: a general population-based cohort study.
    Osteoarthritis and cartilage, 2022, Volume: 30, Issue:4

    Topics: Cohort Studies; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoarthritis, Knee; Pantoprazole; Proton Pump Inhibitors; Rabeprazole

2022
Evolution of the consumption trend of proton pump inhibitors in the Lleida Health Region between 2002 and 2015.
    BMC public health, 2022, 04-24, Volume: 22, Issue:1

    Topics: Aged; Esomeprazole; Female; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors

2022
Solvent-dependent carbon dots for multifunctional sensing of temperature, pH, and proton pump inhibitors.
    Analytica chimica acta, 2022, Oct-02, Volume: 1228

    Topics: Carbon; Esomeprazole; Hydrogen-Ion Concentration; Omeprazole; Phloroglucinol; Proton Pump Inhibitors; Quantum Dots; Rabeprazole; Solvents; Temperature

2022
Time-dependent association between omeprazole and esomeprazole and hospitalization due to hyponatremia.
    European journal of clinical pharmacology, 2023, Volume: 79, Issue:1

    Topics: Case-Control Studies; Esomeprazole; Hospitalization; Humans; Hyponatremia; Omeprazole; Proton Pump Inhibitors

2023
In-vitro antibacterial activity of omeprazole and esomeprazole in combination with ciprofloxacin as an alternative to repositioning against ESKAPE pathogens and evaluation of the cleavage capacity of plasmid DNA.
    International journal of antimicrobial agents, 2023, Volume: 61, Issue:5

    Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA; Esomeprazole; Omeprazole; Plasmids; Proton Pump Inhibitors

2023
Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases.
    Toxicology and applied pharmacology, 2023, 09-15, Volume: 475

    Topics: Adverse Drug Reaction Reporting Systems; Cilostazol; Clopidogrel; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Esomeprazole; Hemorrhage; Humans; Omeprazole; Prasugrel Hydrochloride; United States

2023
CYP2C19 loss-of-function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel.
    Clinical and translational science, 2023, Volume: 16, Issue:10

    Topics: Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Esomeprazole; Genotype; Humans; Omeprazole; Platelet Aggregation Inhibitors; Prospective Studies; Stroke; Treatment Outcome

2023